Key facts
- This page summarizes Neil Gallagher's Form 4 filing for Zymeworks Inc. (ZYME).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Dec 2024, 17:49.
Neil Gallagher - 10 Dec 2024 Form 4 Insider Report for Zymeworks Inc. (ZYME)
- Reporting relationship
- Director
- Issuer ticker
- ZYME
- Reported as of
- 10 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Dec 2024, 17:49:50 UTC
- Prior SEC filing
- 02 Apr 2024
- Next SEC filing
- 07 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Daniel Dex, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Neil Gallagher filed Form 4 for Zymeworks Inc. (ZYME) on 12 Dec 2024.
Change
- Previous filing in this sequence was filed on 02 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZYME
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +31,000
- Change %
- Price
- $0.000000
- Shares after
- 31,000
- Date
- 10 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 31,000
- Exercise price
- $13.06
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Stock options vest on date of next annual general meeting following grant date of December 10, 2024.